Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2202083A Booster in 12-18 Month Olds
NCT01171989Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Primary completion
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GSK2202083A in diphtheria, Tetanus, pertussis and 4 more (3 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) and Number of Seroprotected Subjects Against Neisseria Meningitidis Serogroup C Using Baby Rabbit Complement (rSBA-MenC). Started Aug 2010; status: completed.
02
Drugs
GSK2202083A
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01171989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171989.